Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo. (Q38818271)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26585891%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

title

Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26585891%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26585891%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Penelope D Ottewell

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26585891%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

M Walker

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26585891%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

F Nutter

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26585891%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

A Fowles

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26585891%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

C A Evans

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26585891%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

C L Eaton

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26585891%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

publication date

19 November 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26585891%20AND%20SRC:MED&resulttype=core&format=json

Clinical & Experimental Metastasis

29 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26585891%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26585891%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26585891%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

211-224

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26585891%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

29 February 2020

copyright license

start time

19 November 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Metastasis dormancy in estrogen receptor-positive breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9770-X

Mouse models of breast cancer metastasis to bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9770-X

Anti-tumour effects of bisphosphonates--what have we learned from in vivo models?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9770-X

Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9770-X

Breast-cancer adjuvant therapy with zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9770-X

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9770-X

Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9770-X

Estrogen and bone: osteoclasts take center stage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9770-X

Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9770-X

Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9770-X

Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9770-X

Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9770-X

OPG-Fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9770-X

Loss of plakoglobin promotes decreased cell-cell contact, increased invasion, and breast cancer cell dissemination in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9770-X

Local regulation of human breast xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9770-X

Bisphosphonates induce apoptosis in human breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9770-X

Bisphosphonates induce breast cancer cell death in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9770-X

Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9770-X

Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9770-X

Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9770-X

Zoledronic acid inhibits macrophage/microglia-assisted breast cancer cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9770-X

Direct antitumour activity of zoledronic acid: preclinical and clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9770-X

The backbone of progress--preclinical studies and innovations with zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9770-X

Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9770-X

Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9770-X

Overview of bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9770-X

Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9770-X

Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9770-X

Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9770-X

Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9770-X

Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9770-X

Essential requirement of antigen presentation by monocyte lineage cells for the activation of primary human gamma delta T cells by aminobisphosphonate antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9770-X

Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9770-X

Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9770-X

Update on Estrogens and the Skeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-015-9770-X

Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results

21 January 2018

1 reference

12 December 2020

Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice

1 reference

12 December 2020

Zoledronic acid as an antimetastatic agent for different human tumor cell lines

1 reference

12 December 2020

Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases

1 reference

12 December 2020

Reversal of bone loss in mice by nongenotropic signaling of sex steroids

1 reference

12 December 2020

Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity

1 reference

12 December 2020

The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone

1 reference

12 December 2020

10.1007/S10585-015-9770-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26585891%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

29 February 2020

1046684217

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26585891%20AND%20SRC:MED&resulttype=core&format=json